NEW YORK – Sophia Genetics on Monday said it has entered into a research partnership with the Spanish Lung Cancer Group to identify biomarkers of response to neoadjuvant nivolumab (Bristol Myers Squibb's Opdivo) plus chemo in non-small cell lung cancer patients.